Condition
Acute Intermittent Porphyria (AIP)
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Completed2
Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05502133RecruitingPrimary
Identification of Acute Intermittent Porphyria Modifying Genes
NCT01568554Completed
Clinical Diagnosis of Acute Porphyria
NCT03505853Phase 1CompletedPrimary
A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)
NCT03547297Terminated
INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
Showing all 4 trials